⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 16, 2024World Journal of Clinical OncologyOpen Access

Bibliometric analysis of phosphoglycerate kinase 1 expression in breast cancer and its distinct upregulation in triple-negative breast cancer

Jingyu Chen Jian‐Di Li Rong‐Quan He Zhi-Guang Huang Gang Chen Wen Zou

View Full Paper

Ask AI

Bookmark

Share

Abstract

Phosphoglycerate kinase 1 (PGK1) has been identified as a possible biomarker for breast cancer (BC) and may play a role in the development and advancement of triple-negative BC (TNBC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e60235b6db64358759555c https://doi.org/10.5306/wjco.v15.i7.867

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phosphoglycerate Kinase 1: An Effective Therapeutic Target in Cancer2024 · 19 citations
2Expression of PGK1 in Breast Cancers Alters Their Sensitivity to Ferroptosis Induction via Metabolic ReprogrammingOriginal Research · 2026
3PGK1 dysregulation promotes head and neck cancer progression through p21 downregulationOriginal Research · 2026
4<scp>PGAM1</scp> Orchestrates Cell Cycle Progression, Glycolytic Reprogramming, and Immunosuppressive Microenvironment in Triple‐Negative Breast CancerOriginal Research · 2026
5<scp>PGK1</scp> can affect the prognosis and development of bladder cancer2024 · 4 citations